ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2795

Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study

Anita Boyapati1, Jérôme Msihid2, Emmanuelle Cousin3, Ling Cai4, Janet van Adelsberg1, Jennifer D Hamilton1, Neil Graham5, Tanya Momtahen6 and Stefano Fiore7, 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2Sanofi R&D, France, Chilly-Mazarin, NJ, France, 3Sanofi R&D, France, Chilly-Mazarin, France, 4Sanofi R&D, China, Beijing, China, 5Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6Sanofi, Bridgewater, NJ, 7Distinct Project Unit, Sanofi, Bridgewater, NJ

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic drugs, Biomarkers, IL-6, osteoclasts and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose Rheumatoid arthritis (RA) patients develop bone and joint damage due to chronic inflammation mediated by critical cytokines, eg, IL-6. Pre-clinical studies have implicated IL-6 signaling in regulation of osteoclasts and fibroblast-like synoviocytes (FLS) to increase levels of bone resorptive molecules like receptor activated NF kB ligand (RANKL) and joint destructive proteins, such as matrix metalloproteinases (MMPs). Blockade of IL-6R signaling by sarilumab significantly reduced structural damage in RA patients, as measured by the modified van der Heijde total Sharp Score, including the erosion score and joint space narrowing components in the Phase 3 part of the MOBILITY study (NCT01061736). Most common TEAEs included infections and injection site reactions. A higher incidence of serious infections was observed with sarilumab. Lab abnormalities included decreases in neutrophils and increases in transaminases and lipids. To elucidate mechanisms of clinical reduction of bone and joint damage by sarilumab, we evaluated a panel of serum markers associated with bone resorption (RANKL and osteoprotegerin [OPG]), bone turnover (CTX-1 and C1M), osteoblast formation (osteocalcin [OC]), synovium (MMP-3 and C3M) and cartilage degradation (C2M) in patients enrolled in MOBILITY B.

Methods Sera were analyzed from 128 patients treated with placebo (Pbo) + methotrexate (MTX), and 131 patients receiving subcutaneous 200 mg sarilumab every other week (q2w) + MTX. Serum biomarkers levels were measured by ELISA. All biomarkers were analyzed at baseline, and post-treatment at Wks 2 and 24, with the exceptions of CTX-1 and OC, which were analyzed at baseline, Wks 24 and 52 post-treatment. A mixed effect model with repeated measures on % change from baseline (after rank transformation) was performed for all biomarkers (ANOVA-type method). Treatments were compared at each visit. For samples above the limit of quantitation (LOQ), the LOQ was used in analyses, for samples below the LOQ, half the LOQ was used.

Results Sarilumab + MTX treatment significantly reduced levels of MMP-3 and MMP generated fragments of collagen type 1 and type 3 (C1M and C3M) compared to Pbo + MTX at all timepoints analyzed (Table). RANKL levels were also reduced at Wk 24 in the sarilumab + MTX group, however approximately 15% of values were above the LOQ. In contrast, OC increased from baseline in the sarilumab 200 mg q2w + MTX group compared to Pbo + MTX but did not reach significance (Wk 52, p=0.0571).

Table. Median percent change from baseline

Serum Biomarker

Tissue of Origin

Wk 2

Wk 24

Pbo + MTX (N=128)

Sarilumab 200 mg q2w + MTX (N=131)

Pbo + MTX (N=128)

Sarilumab 200 mg q2w + MTX (N=131)

C1M

Bone

2.30

-50.10*

-8.10

-60.30*

RANKL

Bone

0

-3.95†

0

-23.90†

OPG

Bone

0

-5.60

-1.80

-1.55

C3M

Synovium

-0.35

-23.75*

-5.25

-31.50*

MMP-3

Synovium

-0.35

-5.35†

-2.65

-44.20*

C2M

Cartilage

2.40

-4.30†

0

-4.35

Wk 24

Wk 52

CTX-1

Bone

-7.80

-6.65

-6.95

-7.70

OC

Bone

2.10

10.85

0.10

13.20

p-values generated for Sarilumab 200 mg q2w + MTX vs. Placebo + MTX comparison at each timepoint: * p<0.0001, † p<0.05

Note: for RANKL, 15% of values were above the upper LOQ

Conclusion Sarilumab reduced bone resorption and joint damage markers, and increased OC, a marker of bone formation, in RA patients. This is the first report that IL-6 inhibition leads to RANKL reduction in RA patients. This data supports a mechanism whereby increased IL-6 signaling promotes structural damage through osteoclasts and FLS and by reducing osteoblast bone formation.

 


Disclosure:

A. Boyapati,

Regeneron Pharmaceuticals, Inc,

3,

Regeneron Pharmaceuticals, Inc,

1;

J. Msihid,

Sanofi R&D,

3,

Sanofi R&D,

1;

E. Cousin,

Sanofi R&D,

3,

Sanofi R&D,

1;

L. Cai,

Sanofi R&D,

3;

J. van Adelsberg,

Regeneron Pharmaceuticals, Inc.,

3,

Regeneron Pharmaceuticals, Inc.,

1;

J. D. Hamilton,

Regeneron Pharmaceuticals, Inc.,

1,

Regeneron Pharmaceuticals, Inc,

3;

N. Graham,

Regeneron,

1,

Regeneron,

3;

T. Momtahen,

Sanofi ,

1,

Sanofi ,

3;

S. Fiore,

Sanofi ,

3,

Sanofi ,

1.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/blockade-of-il-6r-signaling-by-sarilumab-suppressed-circulating-markers-of-bone-resorption-and-synovial-damage-in-rheumatoid-arthritis-patients-from-a-phase-3-randomized-double-blind-placebo-contro/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology